MarkA.TaylorMD

Clinical Trials

• Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01

  Completed

  Phase 3

• Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01

  Completed

  Phase 3

• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01

  Active, not recruiting

  Phase 3

• S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma Start of enrollment: 2007 Jul 01

  Completed

  Phase 2

• Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15

  Completed

  Phase 3

• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10

  Active, not recruiting

  Phase 3

• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15

  Completed

  Phase 3

• Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01

  Completed

  Phase 2

• Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18

  Completed

  Phase 2

• Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07

  Completed

  Phase 2

• Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21

  Active, not recruiting

  Phase 2

• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24

  Active, not recruiting

  Phase 3

• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06

  Active, not recruiting

  Phase 3

• Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28

  Completed

  Phase 1, Phase 2

• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08

  Active, not recruiting

  Phase 3

• Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01

  Terminated

  Phase 2

• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01

  Completed

  Phase 2

• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15

  Active, not recruiting

  Phase 3

• Join now to see all